#Sweden #Stockholm #biotechnology #Epigenica #EpiFinder

Epigenica Secures Funding for Future Growth

Epigenica AB, renowned for its innovative high-throughput epigenetic screening solutions, has successfully concluded a significant funding round, raising $2.2 million (SEK 21.5M). This investment will allow Epigenica to advance its commercial efforts and increase its presence in the rapidly evolving biotech market, especially in the United States.

The funding round was primarily led by Voima Ventures, a well-respected Nordic early-stage investor focused on science-based advancements. Other notable participants included Navigare Ventures, recognized for its deep tech investments, Leksell Social Ventures, which emphasizes social impact, and existing shareholder Almi Invest. This array of investors emphasizes the potential anticipated by the market for Epigenica's products and services.

A pivotal aspect of Epigenica's innovation lies within its proprietary EpiFinder platform. This technology enables the simultaneous evaluation of various epigenetic markers across extensive sample sizes with impressive resolution and efficiency. The increasing focus on multi-omics methodologies, involving the comprehensive analysis of RNA, proteins, and metabolites, is enhancing our understanding of biological processes and paving the way for groundbreaking research.

Stina Wallmark, Investment Director at Voima Ventures, highlighted the transformative possibilities that epigenetics holds, indicating its importance in sectors such as oncology, longevity research, and drug development. She emphasized that Epigenica’s offerings facilitate fast and cost-effective analysis of epigenetic biomarkers, thereby unlocking the full potential of multi-omics research in developing new diagnostics and therapies.

Epigenica’s CEO, Mohamad Takwa, expressed excitement about the recent funding, noting that it validates the company’s progress in both scientific advancements and commercial viability. Since its inception, Epigenica has refined its technologies to offer a diverse portfolio of products tailored for multiple epigenetic applications. Takwa projects that the upcoming year will witness several significant product launches designed to enhance and diversify research capacities.

This funding will not only accelerate the development of Epigenica’s flagship products like the currently available EpiFinder Genome and future offerings such as EpiFinder Global and EpiFinder cNUC kits, but will also bolster the company’s service offerings and data infrastructure. Such enhancements are crucial as Epigenica sets its sights on expanding into the U.S. market, which represents a substantial growth opportunity.

In summary, Epigenica AB is poised for an exciting phase of growth fueled by innovative technology and strategic funding. This investment marks a critical step toward expanding not just its market reach but also enhancing collaborative efforts in epigenetic research,
ultimately contributing to groundbreaking advancements in healthcare.